UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)
Launched by UCB PHARMA · Jun 26, 2006
Trial Information
Current as of October 23, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- The subjects must meet the following criteria for registration:
- • Enroll prospectively (patient is still pregnant and no structural defects have been noted on a prenatal test)
- • Exposure to Keppra® and Keppra XR® on or after the first day of the patient's last menstrual period (verified by date or gestational age of exposure)
- • For patient-initiated enrollments, provide verbal or written consent to participate in the Registry
- • For patient-initiated enrollments, provide contact information for herself, her HCP, and the infant's HCP (as applicable)
About Ucb Pharma
UCB Pharma is a global biopharmaceutical company dedicated to discovering and delivering innovative treatments for severe diseases in neurology and immunology. With a strong focus on research and development, UCB leverages cutting-edge science and technology to advance its pipeline of therapies aimed at improving the quality of life for patients. Committed to collaboration and patient-centricity, UCB engages with healthcare professionals and patient communities to ensure its clinical trials address unmet medical needs and contribute to the advancement of healthcare solutions worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wilmington, North Carolina, United States
Patients applied
Trial Officials
Vikki Brown, MD
Principal Investigator
Syneos Health
Jürgen Bentz, PhD
Study Director
UCB Pharma
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials